

## **Xgeva**

## **HMSACOM - Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-237-5512**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-808-254-4414**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect<sup>®</sup> 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do\_not\_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

| Patient's Name:                              | Date:  |
|--|--|
| Patient's ID:                                | Patient's Date of Birth:   |
| Patient's Phone Number:                      |  |
| Physician's Name:                            |  |
| Specialty:                                   |  |
| Physician Office Telephone:                  |  |
| 11 0   | o dosing limits in accordance with FDA-approved labeling, adia, and/or evidence-based practice guidelines. |
| Additional Demographic Information:          |  |
| Patient Weight:                              | kg   |
| Patient Height:ftft                          | inches   |
| Indicate where the drug is being dispensed:  |  |
| ☐ Office ☐ Outpatient Hospital ☐ Am          | ibulatory Surgical   Inpatient Hospital  |
| ☐ Off Campus Outpatient Hospital ☐ U         | Jrgent Care ☐ Emergency Room ☐ Birthing Center   |
| ☐ Military Facility ☐ Skilled Nursing F      | ē .  |
|  | esidential Treatment   |
| ☐ Psychiatric Facility ☐ Pharmacy ☐          |  |
| desychiatric racinty definatinacy d          | Oulei  |
| Indicate where the drug is being administere | <i>d</i> :   |
| ☐ Ambulatory surgical ☐ Home ☐ Inp           |  |
| ☐ Office ☐ Outpatient Hospital ☐ Phar        |  |
| - Office - Outpatient Hospital - Filal       | macy   |
| What is the ICD-10 code?                     |  |

## **Criteria Questions:**

| Giant cell tumor of the bone, Continue to #2 Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., reast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), Continue to #2 Hypercalcemia of malignancy, Continue to #2 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, Continue to #2 Palliative care for bone metastases from thyroid carcinoma, Continue to #2 Other, Continue to #2 List is request for a new start or continuation of Xgeva therapy? New start, Continue to #4 Continuation, Continue to #3 List Was Xgeva therapy previously authorized by HMSA/CVS for this member? No, Continue to #101 No, Continue to #4 Unknown, Continue to #4 List what is the patient's diagnosis? Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). Wo Further Questions Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of fryorid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED: |
|--|
| Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, Continue to #2 Palliative care for bone metastases from thyroid carcinoma, Continue to #2 Other, Continue to #2  Is this request for a new start or continuation of Xgeva therapy? New start, Continue to #4 Continuation, Continue to #3  S. Was Xgeva therapy previously authorized by HMSA/CVS for this member? Yes, Continue to #101 No, Continue to #4 Unknown, Continue to #4  What is the patient's diagnosis? Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment allbumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| Department of the bone metastases from thyroid carcinoma, Continue to #2  Other, Continue to #2  Is this request for a new start or continuation of Xgeva therapy?  New start, Continue to #4  Continuation, Continue to #3  Was Xgeva therapy previously authorized by HMSA/CVS for this member?  Yes, Continue to #101  No, Continue to #4  Unknown, Continue to #4  What is the patient's diagnosis?  Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions.  Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:   |
| Other, Continue to #2  Is this request for a new start or continuation of Xgeva therapy?  New start, Continue to #4  Continuation, Continue to #3  Was Xgeva therapy previously authorized by HMSA/CVS for this member?  Yes, Continue to #101  No, Continue to #4  Unknown, Continue to #4  What is the patient's diagnosis?  Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions.  Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:   |
| New start, Continue to #4 Continuation, Continue to #3 Was Xgeva therapy previously authorized by HMSA/CVS for this member? Yes, Continue to #101 No, Continue to #4 Unknown, Continue to #4 Unknown, Continue to #4 Unknown, Continue to #4 Unknown of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| New start, Continue to #4 Continuation, Continue to #3  Was Xgeva therapy previously authorized by HMSA/CVS for this member? Yes, Continue to #101 No, Continue to #4 Unknown, Continue to #4  What is the patient's diagnosis? Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., creast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| Continuation, Continue to #3  3. Was Xgeva therapy previously authorized by HMSA/CVS for this member?  3. Yes, Continue to #101  3. No, Continue to #4  4. Unknown, Continue to #4  5. What is the patient's diagnosis?  6. Giant cell tumor of the bone, No Further Questions  7. Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions.  6. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions  6. Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  6. Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| 3. Was Xgeva therapy previously authorized by HMSA/CVS for this member?  3. Yes, Continue to #101  3. No, Continue to #4  4. Unknown, Continue to #4  5. What is the patient's diagnosis?  6. Giant cell tumor of the bone, No Further Questions  7. Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions.  6. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions  6. Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  6. Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| Yes, Continue to #101 No, Continue to #4 Unknown, Continue to #4  What is the patient's diagnosis? Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., reast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| Unknown, Continue to #4  What is the patient's diagnosis?  Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:   |
| Unknown, Continue to #4  What is the patient's diagnosis?  Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., oreast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:   |
| Giant cell tumor of the bone, <i>No Further Questions</i> Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), <i>ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate).</i> Palliative care for bone metastases from thyroid carcinoma, <i>ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions</i> Hypercalcemia of malignancy, <i>ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5</i> Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, <i>ACTION REQUIRED:</i>   |
| Giant cell tumor of the bone, No Further Questions Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). No Further Questions. Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
| Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), ACTION REQUIRED: Please submit documentation of primary cancer from patient's chart notes (e.g., breast, prostate). Further Questions.  Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions  Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:   |
| Palliative care for bone metastases from thyroid carcinoma, ACTION REQUIRED: Please submit documentation of thyroid carcinoma from patient's chart notes. No Further Questions  Hypercalcemia of malignancy, ACTION REQUIRED: Please submit documentation of pre-treatment albumin-corrected serum calcium level. Continue to #5  Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis, ACTION REQUIRED:  |
|  |
| Please submit documentation of systemic mastocytosis and pre-treatment T-score. No Further Questions   |
| Solution is the patient's condition refractory to IV bisphosphonate therapy?  Solution Yes, No Further Questions  No, Continue to #6   |
| 3 No, Continue to #0   |
| 5. Is there a clinical reason to avoid treatment with an IV bisphosphonate (e.g., acute renal impairment, renal insufficiency [creatinine clearance < 35 ml/min], history of intolerance to an IV bisphosphonate)?  3 Yes, No Further Questions  3 No, No Further Questions  |
| CONTINUATION CRITERIA  |
| 01. What is the diagnosis?  Giant cell tumor of the bone, <i>Continue to #102</i> Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., preast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer), <i>No Further Questions</i>   |
| Palliative care for bone metastases from thyroid cancer, <i>No Further Questions</i>   |

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xgeva HMSACOM – 04/2024.

| Prescriber or Authorized Signature   | Date (mm/dd/yy)                        |
|--|--|
| X  | <del></del>                            |
| I attest that this information is accurate and true, and the information is available for review if requested by CVS C |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
| ☐ Yes, No Further Questions ☐ No, No Further Questions   |  |
| 103. Is the patient benefiting from therapy as evidenced by disc.  | ease stability or disease improvement? |
| □ No, No Further Questions   |  |
| 102. Is the patient benefiting from therapy as evidenced by disc ☐ Yes, <i>No Further Questions</i>                    | ease stability or disease improvement? |
| ☐ Treatment for osteopenia or osteoporosis in patients with sys  | stemic mastocytosis, Continue to #102  |
|  |  |

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xgeva HMSACOM – 04/2024.